Presentation is loading. Please wait.

Presentation is loading. Please wait.

Interaction between reboxetine and ADRA2B genotype influences post-treatment symptoms of irritability, anxiety, and dizziness. Interaction between reboxetine.

Similar presentations


Presentation on theme: "Interaction between reboxetine and ADRA2B genotype influences post-treatment symptoms of irritability, anxiety, and dizziness. Interaction between reboxetine."— Presentation transcript:

1 Interaction between reboxetine and ADRA2B genotype influences post-treatment symptoms of irritability, anxiety, and dizziness. Interaction between reboxetine and ADRA2B genotype influences post-treatment symptoms of irritability, anxiety, and dizziness. A, Significant decrease in post-treatment irritability in ADRA2B deletion carriers under placebo that was absent in nondeletion carriers. B, Significant decrease in anxiety in ADRA2B deletion carriers under placebo compared with reboxetine. C, Significant increase in dizziness in ADRA2B nondeletion carriers under reboxetine compared with placebo. *p < **p < ***p < Bars indicate SEM. Ayana A. Gibbs et al. J. Neurosci. 2013;33: ©2013 by Society for Neuroscience


Download ppt "Interaction between reboxetine and ADRA2B genotype influences post-treatment symptoms of irritability, anxiety, and dizziness. Interaction between reboxetine."

Similar presentations


Ads by Google